Volume 20, Number 6—June 2014
CME ACTIVITY - Synopsis
Adverse Pregnancy Outcomes and Coxiella burnetii Antibodies in Pregnant Women, Denmark
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at www.medscape.org/journal/eid; (4) view/print certificate.
Release date: May 14, 2014; Expiration date: May 14, 2015
Upon completion of this activity, participants will be able to:
• Describe adverse outcomes of pregnancies with positive or increasing titers against C. burnetii, based on a case series from Denmark
• Distinguish the causal association between adverse pregnancy outcomes and C. burnetii infection
• Assess the overall risk for a Q fever–associated adverse pregnancy outcome.
Shannon O’Connor, ELS, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Shannon O’Connor has disclosed no relevant financial relationships.
Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.
Disclosures: Stine Yde Nielsen, MD, PhD; Kåre Mølbak, MD, DMSc; Tine Brink Henriksen, PhD; and Karen Angeliki Krogfelt, PhD, have disclosed no relevant financial relationships. Carsten Schade Larsen, DMSc, has disclosed the following relevant financial relationships: served as a speaker or a member of a speakers bureau for GlaxoSmithKline, Gilead; received grants for clinical research from CSL Behring. Steen Villumsen, MD, PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for and received grants for clinical research from Statens Serum Institut.
- Page created: May 14, 2014
- Page last updated: May 14, 2014
- Page last reviewed: May 14, 2014
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)